Wall Street analysts expect Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) to announce $1.18 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Syneos Health’s earnings, with estimates ranging from $1.15 to $1.21. Syneos Health reported earnings per share of $0.97 in the same quarter last year, which would suggest a positive year-over-year growth rate of 21.6%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Syneos Health will report full year earnings of $5.09 per share for the current year, with EPS estimates ranging from $4.91 to $5.20. For the next fiscal year, analysts anticipate that the firm will report earnings of $5.71 per share, with EPS estimates ranging from $5.42 to $5.95. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Syneos Health.
Syneos Health (NASDAQ:SYNH – Get Rating) last issued its quarterly earnings data on Friday, April 29th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.06. Syneos Health had a net margin of 4.54% and a return on equity of 13.33%. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the company posted $0.66 EPS. The business’s revenue was up 10.5% on a year-over-year basis.
Syneos Health stock opened at $75.71 on Thursday. The firm has a 50-day moving average price of $78.53 and a 200-day moving average price of $88.55. The firm has a market capitalization of $7.76 billion, a PE ratio of 32.77 and a beta of 1.79. The company has a current ratio of 1.09, a quick ratio of 1.07 and a debt-to-equity ratio of 0.89. Syneos Health has a 12-month low of $66.77 and a 12-month high of $104.18.
Several institutional investors have recently modified their holdings of SYNH. Silvercrest Asset Management Group LLC grew its position in shares of Syneos Health by 490.6% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,427,767 shares of the company’s stock worth $145,924,000 after buying an additional 1,186,001 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Syneos Health by 576.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,343,624 shares of the company’s stock worth $137,963,000 after buying an additional 1,144,983 shares during the last quarter. Norges Bank purchased a new position in shares of Syneos Health in the 4th quarter worth approximately $101,693,000. BlackRock Inc. grew its position in shares of Syneos Health by 7.7% in the 4th quarter. BlackRock Inc. now owns 9,910,450 shares of the company’s stock worth $1,017,605,000 after buying an additional 707,665 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Syneos Health by 42.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,200,361 shares of the company’s stock worth $192,488,000 after purchasing an additional 653,520 shares during the last quarter. 98.38% of the stock is currently owned by hedge funds and other institutional investors.
About Syneos Health (Get Rating)
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.